Stopped
PCS6422 With Capecitabine · Advanced or Metastatic Breast Cancer
Trial terminated
Also in this update: Final enrollment: 20 participants (planned 90); Primary completion date changed from estimate of Sep 2026 to Jul 29, 2026
Processa PharmaceuticalsPhase 2 NCT06568692 Registry history of NCT06568692 on ClinicalTrials.gov (opens the registry)